Metsera, Inc. MTSR
At closeNov 13, 2025, 4:00 PM EST
52-week range unavailable
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 7.43B
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 27.87M
- Open
- 70.74
- Previous close
- 70.50
- Day's range
- 70.13 – 70.76
- Earnings date
- Mar 25, 2026
2Y +44.00 (+166.04%)
Key statistics
- Enterprise value
- 6.98B
- PEG ratio
- -16.63
- Price / sales
- 0.00
- Price / book
- 21.96
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -47.04%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 25, 2026
Expected Mar 25, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 25, 2026 | Dec 31, 2025 | -0.54 | — | — | — |
| Nov 12, 2025 | Sep 30, 2025 | -0.56 | -1.11 | -0.55 | -98.21% |
| Jul 28, 2025 | Jun 30, 2025 | -0.65811 | -0.66 | 0.00 | -0.29% |
| May 12, 2025 | Mar 31, 2025 | -0.85 | -1.03 | -0.18 | -21.18% |
| Mar 26, 2025 | Dec 31, 2024 | -0.80 | -3.52 | -2.72 | -340.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 24, 2025 | Leerink Partners | down | Outperform | Market Perform |
| Sep 9, 2025 | Leerink Partners | init | — | Outperform |
| Sep 3, 2025 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 28, 2025 | B of A Securities | main | Buy | Buy |
| Jun 20, 2025 | Wells Fargo | init | — | Overweight |
| Jun 10, 2025 | Guggenheim | main | Buy | Buy |
About Metsera, Inc.
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 93
- Website
- pfizer.com
News
Deal Dispatch: Warner Bros., Bill.com, C3 AI—Key Auctions And Buyouts Shake The Market 
Ozempic Maker Novo Nordisk Faces Board Shakeup 
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields 
12 Health Care Stocks Moving In Monday's Intraday Session - 12 Health Care Stocks Moving In Monday's Pre-Market Session
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket 
10 Health Care Stocks Whale Activity In Today's Session - 12 Health Care Stocks Moving In Thursday's Intraday Session
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday
Your note
Sign in to keep a note on MTSR — it syncs with the Stock Master app.